Cellosaurus cell line NT-18LM (CVCL

Cross-references
Cell line name	NT-18LM
Accession	CVCL_C4N5
Resource Identification Initiative	To cite this cell line use: NT-18LM (RRID:CVCL_C4N5)
Comments	Doubling time: 6.35 days (PubMed=36269546). Derived from site: Metastatic; Liver; UBERON=UBERON_0002107.
Sequence variations	Mutation; HGNC; HGNC:2681; DAXX; Simple; p.Cys629Leufs*29 (c.1884dupC); Zygosity=Unspecified (PubMed=36269546). Mutation; HGNC; HGNC:7010; MEN1; Simple; p.Arg29Ter (c.85C>T); ClinVar=VCV000200970; Zygosity=Unspecified (PubMed=36269546). Mutation; HGNC; HGNC:11633; TCF3; Simple; p.Lys101Arg (c.302A>G); ClinVar=VCV000810990; Zygosity=Unspecified (PubMed=36269546).
Disease	Pancreatic neuroendocrine tumor G3 (NCIt: C172814) Neuroendocrine tumor of pancreas (ORDO: Orphanet_97253)
Species of origin	Homo sapiens (Human) (NCBI Taxonomy: 9606)
Originate from same individual	CVCL_C4N6 ! NT-18P CVCL_C4N7 ! NT-36
Sex of cell	Male
Age at sampling	56Y
Category	Cancer cell line
Publications	PubMed=36269546; DOI=10.1007/s13402-022-00727-z; PMCID=PMC9747820 Viol F., Sipos B., Fahl M., Clauditz T.S., Amin T., Kriegs M., Nieser M., Izbicki J.R., Huber S., Lohse A.W., Schrader J. Novel preclinical gastroenteropancreatic neuroendocrine neoplasia models demonstrate the feasibility of mutation-based targeted therapy. Cell. Oncol. (Dordr.) 45:1401-1419(2022)
Encyclopedic resources	Wikidata; Q116050014
Entry history
Entry creation	15-Dec-2022
Last entry update	19-Dec-2024
Version number	4